The Tumor Necrosis Factor Receptor Superfamily Member 18 pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Receptor Superfamily Member 18 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, and Infectious Disease which include the indications Solid Tumor, Oncology, Autoimmune Disorders, and Infectious Disease. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Receptor Superfamily Member 18 pipeline targets constitutes close to 15 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 7, and 5 respectively.
Tumor Necrosis Factor Receptor Superfamily Member 18 overview
Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway.
For a complete picture of Tumor Necrosis Factor Receptor Superfamily Member 18’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
